Optimal Further Strengthens Operations with New Global Sales Manager, Chris Vickers

Optimal further strengthens operations with new global sales manager

Process Analytical Technology (PAT) leader, Optimal Industrial Technologies, is increasing its support for the growing global demand for data-driven, automated process control strategies with the appointment of Chris Vickers. As global sales manager, he will be responsible for creating new business opportunities while continuing to serve existing customers, enhancing the company’s ability to deliver unparalleled value.

As a leading specialist in PAT and creator of the award-winning, market-leading software, synTQ, Optimal is committed to helping its customers realise the benefits of advanced analytics and real-time process monitoring. In essence, the company aims to drive the competitiveness of organisations across industry and around the world in the digital era. The addition of Chris Vickers to the team signifies the Optimal’s dedication to exceeding customer expectations through high-quality, comprehensive support.

With over 38 years of experience in sales leadership and a profound understanding of the instrumentation and control sector, Chris Vickers possesses the vision and strategic acumen necessary to guide Optimal’s customers to new heights. By leveraging his expertise in both highly regulated and fast-paced reactive industries, the new global sales manager will be instrumental in ensuring that every customer benefits from solutions tailored to their specific requirements, ultimately enabling them to optimise their processes and enhance operational efficiency.

Martin Gadsby, VP at Optimal, comments: “In addition to manufacturers looking to adopt PAT, we are seeing global customers interested in expanding their PAT-driven frameworks to improve multiple lines and plants. Chris Vickers has a proven ability to engage with experts in a variety of industries and intuitively understand their requirements. These capabilities make him the ideal candidate to strengthen existing customer relationships and forge new collaborations. We are extremely delighted to have him on our team and excited to see what we can achieve together.”

Chris Vickers concludes: “I am honoured to join Optimal and be part of an organisation that is at the forefront of PAT and enabling technologies for smart manufacturing. synTQ can help companies gain unparalleled advantages, from driving profitability to shortening time-to-market and improving efficiency while reducing waste. I’d like to invite anyone interested in joining the ranks of the industry leaders who are already using PAT and synTQ to address bottlenecks, transform their businesses and stay ahead of the competition to get in touch with me. I look forward to developing the right solution for you!”

Hot this week

Medtronic Expands AiBLE Spine Surgery Ecosystem with New Technologies and Siemens Healthineers Partnership

New advancements in the AiBLE Spine Surgery ecosystem build upon the company's commitment to procedural innovation and execution

Axlab, Danish Medtech Pioneer, expands to US with Advanced Robotic Tissue Sectioning for Pathology Laboratories

Kris Rokke, National Sales Director for Axlab in the US. "My team and I are extremely excited and honored about this unique opportunity to also offer this advanced technology to labs across the US and thus contribute to the pathology labs of tomorrow."

Spartan Medical Broadens Single-Use Sterile Instrument Portfolio to Improve Outcomes, Increase Efficiency, and Generate Cost Savings

Spartan Medical products portfolio of single-use, sterile med tech includes micro and minor surgical convenience kits, kerrison rongeurs, spinal and general surgical retractors, dural repair kits, synthetic biologics, and a wide range of orthopedic pre-sterilized implants and devices.

Recor Medical Supports European Society of Cardiology’s Hypertension Guidelines

Record Medical notes the new guidelines, "2024 ESC Guidelines for the management of elevated blood pressure and hypertension," have been published online and recommend the consideration of renal denervation (RDN) as a safe and effective treatment option for patients who have uncontrolled resistant hypertension or those that have uncontrolled hypertension with a higher risk of cardiovascular disease, who express a preference to undergo RDN.

ConTIPI Medical Selects EVERSANA to Support U.S. Commercialization of Non-Surgical Medical Device ProVate for Women with Pelvic Organ Prolapse

EVERSANA is a leading provider of global commercial services to the life sciences industry, to support commercialization for the ProVate device in the United States to help women experiencing pelvic organ prolapse.